Breast cancer lncRNA prognosis model taking gene mutation as background

By comparing the differences in lncRNA between the genostable and unstable groups of breast cancer patients, an lncRNA prognosis model was constructed, and the risk value was calculated using the expression of specific lncRNAs, which solved the problem of breast cancer prognosis prediction and achieved accurate risk of breast cancer patients Distinguishing and survival rate predictions provide new targets for breast cancer treatment.

CN118932052APending Publication Date: 2024-11-12PEKING UNION MEDICAL COLLEGE HOSPITAL
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410920899.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-10
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art is difficult to effectively use lncRNA to predict the prognosis of breast cancer, and there are few researches on the relationship between lncRNA and genomic instability in breast cancer, and there is a lack of effective prediction and therapeutic targets.

Method used

By comparing the differences in lncRNA expression between the genostatic group and the unstable group of breast cancer patients, lncRNA related to genomic instability was screened out, and a lncRNA breast cancer prognosis model was constructed. AL645608.7, U62317.4, MIR210HG, MAPT-AS1, etc. were used, and AL645608.7, U62317.4, MIR210HG, MAPT-AS1, etc. The expression of lncRNA is calculated to distinguish between high-risk and low-risk patients.

Benefits of technology

This model can accurately distinguish the prognosis of breast cancer patients, significantly improve the accuracy of overall survival prediction in high-risk patients, and provides new prediction and therapeutic targets for future research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118932052A_ABST
    Figure CN118932052A_ABST
Patent Text Reader

Abstract

The lncRNA has an important function in the formation and metastasis processes of tumors. The research on the action of lncRNA in breast cancer is not common yet, and the mechanism is far unclarified. Genome instability is a novel therapeutic target for breast cancer. The lncRNA model related to breast cancer gene instability and prognosis is expected to be found and verified, and a new target spot is provided for judging breast cancer prognosis and treating breast cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to a method for constructing a lncRNA breast cancer prognosis prediction model. Background Art

[0002] Breast cancer has become the number one cancer in women. According to the latest statistics, there were approximately 2.3 million new cases in 2020. One in every four new cancer patients in women suffers from breast cancer. Although classic treatments for breast cancer, such as chemotherapy, radiotherapy, and endocrine therapy, have significantly improved the survival rate of breast cancer. However, the mortality rate of breast cancer is still high. One in every six female cancer deaths is from breast cancer. There is still an urgent need to find new targets and therapeutic drugs for breast cancer patients. Among new drug research, drugs targeting gene mutations are currently a hot topic. For example, drugs targeting BRCA1 / 2 and PIK3CA mutations have significantly improved the survival of patients with advanced breast cancer. Therefore, continuing to look for new drugs targeting gene mutations is of great significance to the treatment of breast cancer.

[0003] Errors in chromosome segregation during cell mitosis lead to aneuploid mutations of the entire chromosome in the daughter cells, or DNA damage causes changes in chromosome structure, resulting in gene translocation, deletion, inversion, and breakage, which are collectively referred to as genomic instability. In fact, almost all tumor cells are accompanied by genomic instability, and about 2 / 3 of human tumors experience genomic instability during cell division. Genomic instability promotes heterogeneity between and within tumors and is the main driving force for the survival, proliferation, and spread of cancer cells.

[0004] Genomic instability, including changes in the number and structure of the genome, is often observed in breast cancer cells. The molecular basis of genetic instability in breast cancer is being widely studied. Some studies have outlined the common manifestations of genomic instability in patients with metastatic breast cancer and used liquid biopsy methods to detect genomic instability. Other studies have reported a new genomic instability derived from miRNA signals in extracellular vesicles, which can serve as a good minimally invasive biomarker for judging poor prognosis and early diagnosis of breast cancer.

[0005] lncRNA (Long non-coding RNA) plays an important role in regulating gene expression at the epigenetic, transcriptional and post-transcriptional levels. Changes in lncRNA expression levels may lead to various diseases, including malignant tumors. It has been confirmed that the dysregulation of lncRNA is involved in the occurrence and drug resistance of various tumors, including breast cancer. Studies have found that NORAD-lncRNA plays a vital role in genome stability. LncRNA CUPID1 and CUPID2 are mainly expressed in hormone receptor-positive breast tumors and play an important role in regulating the repair of double-strand breaks. At present, a large number of lncRNAs are still being discovered, but in breast cancer, the relationship between lncRNA and genome instability is less studied and still needs extensive and in-depth exploration.

[0006] Our study compared the lncRNAs between the unstable and stable groups of breast cancer patients, found lncRNAs with significant differences, constructed and verified the lncRNA prognostic model, and thus helped to judge the prognosis of breast cancer and facilitate further research in the future. Summary of the invention

[0007] The present invention aims to provide a method for judging the prognosis of breast cancer based on a lncRNA scoring model. The technical solution adopted by the present invention is as follows:

[0008] The present invention provides 129 lncRNAs with significant expression differences between a gene stable group and an unstable group, of which 69 lncRNAs are downregulated and 60 lncRNAs are upregulated.

[0009] A group of lncRNAs associated with breast cancer prognosis were also provided: AL645608.7, U62317.4, MIR210HG, and MAPT-AS1.

[0010] The present invention provides a lncRNA breast cancer prognosis model: [AL645608.7 expression amount*0.0711]+[U62317.4 expression amount*(-0.8123)]+[MIR210HG expression amount*0.1581]+[MAPT-AS1 expression amount*(-0.3981)].

[0011] When the risk value is >1.2748, it is high risk, and when the risk value is <1.2748, it is low risk. The overall survival rate of high-risk patients is significantly lower than that of low-risk patients.

[0012] The present invention provides a method for constructing a lncRNA scoring model to judge the prognosis of breast cancer:

[0013] (1) Data collection: Screen samples containing both mRNA and lncRNA. Randomly divide the samples into a training group and a validation group to establish a prognostic model for lncRNA;

[0014] (2) Searching for lncRNAs associated with genomic instability:

[0015] The samples with gene mutation frequency higher than 25% in the screened breast cancer patients were taken as the gene unstable group, and the samples with gene mutation frequency lower than 25% were taken as the gene stable group. The difference in lncRNA expression between the two groups was compared, and false discovery rate (FDR) < 0.05, log fold change > 1 or < -1 were used as the conditions for screening differential lncRNAs, and differential lncRNAs related to genomic instability were obtained;

[0016] (3) Construct and validate a lncRNA prognostic model associated with genomic instability: Among the differentially expressed lncRNAs, combined with the prognostic information in the training group, univariate COX analysis and multivariate COX analysis were used to construct a lncRNA gene prognostic model; using samples from the validation group, the risk value of each patient was calculated based on the gene expression level and the COX regression coefficient in the model, and the patients were divided into high-risk and low-risk groups based on the median, and the prognostic value of the model was evaluated in combination with the clinical prognostic information of the samples;

[0017] (4) Relationship between lncRNA prognostic model and mutation: Comparison of differences in gene mutation frequencies between high-risk and low-risk groups differentiated by the lncRNA prognostic model;

[0018] The specific evaluation method is: measuring the expression of lncRNA in breast cancer patients: AL645608.7, U62317.4, MIR210HG, MAPT-AS1, and substituting the above expression into the formula for calculation:

[0019] [AL645608.7 expression level*0.0711]+[U62317.4 expression level*(-0.8123)]+[MIR210HG expression level*0.1581]+[MAPT-AS1 expression level*(-0.3981)]. The prognosis of breast cancer was judged based on the results. When the risk value was >1.2748, it was high risk, and when the risk value was <1.2748, it was low risk. The overall survival rate of high-risk patients was significantly lower than that of low-risk patients.

[0020] Beneficial effects of the present invention: The model can accurately distinguish the prognosis of patients and provide new prediction and treatment targets for future research. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1.Difference in mutation frequency between the genetically stable group and the genetically unstable group. GS-like: genetically stable group, GU-like: genetically unstable group.

[0022] Figure 2a The 20 most significantly up-regulated and down-regulated genes between the gene stable group and the unstable group, GS-like: gene stable group, GU-like: gene unstable group.

[0023] Figure 2b All 986 samples were clustered according to the differential expression of lncRNAs and grouped according to the frequency of gene mutations, GS-like: gene stable group, GU-like: gene unstable group.

[0024] Figure 3a Overall survival rates of high-risk and low-risk groups of patients in the training group;

[0025] Figure 3b Overall survival rates of high-risk and low-risk groups in the validation group;

[0026] Figure 3c Overall survival rates in high-risk and low-risk groups for all patients.

[0027] Figure 4 .ROC curve of the lncRNA prognostic model in all patients.

[0028] Figure 5a . In the training group, the relationship between the risk value of each patient and the expression of lncRNA in the model was calculated according to the lncRNA prognostic model;

[0029] Figure 5b . In the validation group, the relationship between the risk value of each patient and the expression of lncRNA in the model was calculated based on the lncRNA prognostic model;.

[0030] Figure 5c .The relationship between the risk value calculated by the lncRNA model and the frequency of somatic mutations for each patient in the training group (red for high risk and blue for low risk);

[0031] Figure 5d .The relationship between the risk value calculated by the lncRNA model and the frequency of somatic mutations for each patient in the test group (red for high risk, blue for low risk);

[0032] Figure 6a . Differences in somatic mutation frequencies between high-risk and low-risk groups in the training set distinguished by the lncRNA model;

[0033] Figure 6b.Differences in somatic mutation frequencies between high-risk and low-risk groups in the validation set based on the lncRNA model.

[0034] Figure 7a .Comparison of overall survival between high-risk group and low-risk group in patients aged 65 years or younger;

[0035] Figure 7b .Comparison of overall survival between high-risk and low-risk groups in patients aged ≥65 years;

[0036] Figure 7c .Comparison of overall survival rates between high-risk group and low-risk group in patients with stage T1-2;

[0037] Figure 7d .Comparison of overall survival rates between high-risk group and low-risk group in N0 stage patients;

[0038] Figure 7e .Comparison of overall survival rates between high-risk group and low-risk group in patients with N1-3 stage;

[0039] Figure 7f .Comparison of overall survival rates between high-risk group and low-risk group in M0 stage patients. DETAILED DESCRIPTION

[0040] Example 1

[0041] Clinical information such as patient age, tumor size, lymph node metastasis stage, distant metastasis, and long-term follow-up results were extracted from the TCGA (https: / / portal.gdc.cancer.gov / repository) database, and a total of 1,165 samples containing both mRNA and lncRNA were obtained. 981 samples with both lncRNA and breast cancer survival information were extracted from the TCGA database, and a total of 986 samples of breast cancer patients with gene mutations were extracted from the TCGA database. The 981 samples with both lncRNA and breast cancer survival information in the TCGA database were randomly divided into a training group and a validation group. There were 492 samples in the training group and 489 samples in the validation group. The training group was used to establish a prognostic model for lncRNA.

[0042] Example 2 Searching for lncRNAs associated with genomic instability

[0043] The number of gene mutation sites in each breast cancer patient sample in the TCGA database was counted and sorted. Samples with a gene mutation frequency higher than 25% were considered as the gene unstable group, and samples with a gene mutation frequency lower than 25% were considered as the gene stable group, for a total of 490 samples. Among them, 455 samples were found to contain both lncRNA and gene mutation. The difference in lncRNA expression between the two groups was compared, and FDR<0.05 and log fold change>1or<-1 were used as the conditions for screening differential lncRNAs, and 129 differential lncRNAs associated with genomic instability were obtained.

[0044] Comparing the gene mutation frequencies of all breast cancer patient samples in TCGA, there are significant differences in mutation frequencies between the gene stable group and the unstable group, see Figure 1 , p<2.22e-16.

[0045] Comparison of gene mutations in breast cancer samples in the TCGA database, 250 samples with gene mutation frequencies above 25% and 240 samples with gene mutation frequencies below 25%, comparison of lncRNA differential expression between the two groups, 129 lncRNAs with significant expression differences between the two groups were obtained, of which 69 lncRNAs were downregulated and 60 lncRNAs were upregulated. The top 20 lncRNAs with the most significant upregulation and downregulation were taken, and the differences in expression of these 40 lncRNAs in all samples were compared, and the samples were grouped according to the mutation frequency of the gene. The results are shown in Figure 2a At the same time, the samples in the gene unstable group and the gene stable group were clustered according to the expression levels of differential lncRNAs. The results are shown in Figure 2b .

[0046] Example 3 Construction and verification of lncRNA prognostic model associated with genomic instability

[0047] Model construction method: Among the differentially expressed lncRNAs obtained, combined with the prognostic information in the TCGA clinical database training group established in Example 1, univariate COX analysis and multivariate COX analysis were used to construct a lncRNA prognostic model.

[0048] Verification model method: Using the samples in the validation group in the TCGA clinical database established in Example 1, the risk value of each patient was calculated according to the gene expression level and the COX regression coefficient in the model, and the patients were divided into high-risk group and low-risk group according to the median, so as to evaluate the prognostic value of the model.

[0049] Model construction: The training group contained 492 samples, and the validation group contained 489 samples. There was no significant difference in the basic clinical characteristics between the training group and the validation group, including age and TNM stage. In the training group, among the lncRNAs significantly associated with gene mutations in breast cancer patients, univariate COX analysis was used to find lncRNAs significantly associated with prognosis, and then multivariate COX regression was used to construct a lncRNA model associated with prognosis. The model formula was obtained: [AL645608.7 expression * 0.0711] + [U62317.4 expression * (-0.8123)] + [MIR210HG expression * 0.1581] + [MAPT-AS1 expression * (-0.3981)].

[0050] Verification model results: According to the model formula, the risk values ​​of all breast cancer patients were calculated, and the patients were divided into high-risk and low-risk groups according to the median value of the risk value (1.2748). In the training group, the overall survival rate (OS) of the high-risk group was significantly lower than that of the low-risk group ( Figure 3a , p<0.001). The OS of the high-risk group in the training group and all patients was significantly lower than that of the low-risk group ( Figure 3b , p=0.005, Figure 3c , p<0.001).

[0051] Subsequently, the area under the ROC curve of the lncRNA prognostic model was calculated to be 0.804 in all breast cancer patients in TCGA (see Figure 4 ), which is higher than the lncRNA prognostic model in the current state of the art.

[0052] Example 4 Relationship between lncRNA prognostic model and mutation

[0053] According to the lncRNA prognostic model, breast cancer patient samples from the TCGA database were divided into high-risk and low-risk groups, and then the differences in gene mutation frequencies between the two groups of samples were compared.

[0054] Relationship between LncRNA prognostic model and gene instability

[0055] The lncRNA prognostic model was used to calculate the risk of breast cancer patients in the training group and the validation group in Example 1. The relationship between the risk value of each patient in the training group and the validation group and the expression level of the lncRNA included in the model was observed (see Figure 5a , Figure 5b ); observe the relationship between the risk value and genomic mutation of each patient in the training group and the validation group (see Figure 5c , Figure 5d). In the training group and validation group, the constructed lncRNA model was used to divide the patients into high-risk group and low-risk group. In the training group or validation group, the gene mutation frequencies between the high-risk group and the low-risk group were compared. It was found that the gene mutation frequencies of patients in the high-risk group were significantly higher than those in the low-risk group in both the training group and the validation group (see Figure 6a ,p=0.0071; Figure 6b ,p=0.00045).

[0056] Example 5 Validation of the prognostic model of lncRNA

[0057] Univariate COX analysis and multivariate COX analysis were used to analyze the relationship between clinical characteristics and prognosis, including the prognostic model, in breast cancer samples from the TCGA database. The lncRNA prognostic model was found to be an independent prognostic factor independent of age and stage (Table 1). In the TCGA database, breast cancer samples were grouped according to clinical characteristics based on age, T stage, and N stage. The constructed lncRNA model was applied in different groups to divide the patients into two groups, high-risk and low-risk. It was found that among breast cancer patients aged ≤ 65, the OS of the high-risk group was significantly lower than that of the low-risk group ( Figure 7a ), among breast cancer patients aged > 65, the OS of high-risk group was significantly lower than that of low-risk group ( Figure 7b ), the OS of high-risk patients in T1-2 breast cancer patients was significantly lower than that of low-risk patients ( Figure 7c ), the OS of high-risk patients in N0 breast cancer patients was significantly lower than that of low-risk patients ( Figure 7d ), the OS of N1-3 breast cancer patients in the high-risk group was significantly lower than that in the low-risk group ( Figure 7e ), the OS of high-risk patients in M0 breast cancer patients was significantly lower than that of low-risk patients ( Figure 7f ).

[0058] Table 1 Univariate COX and multivariate COX analysis of lncRNA prognostic models and the relationship between age, stage and prognosis

[0059]

[0060] Conclusion: The lncRNA prognostic model, which is closely related to breast cancer gene mutations, can accurately distinguish high-risk and low-risk groups of breast cancer patients, and provides new prediction and treatment targets for future research.

Claims

1. A lncRNA breast cancer prognosis model, characterized in that: The expression levels of the following lncRNAs in breast cancer patients were measured: AL645608.7, U62317.4, MIR210HG, and MAPT-AS1. The expression levels of the above lncRNAs were substituted into the formula to calculate the risk value: [AL645608.7 expression level × 0.0711] + [U62317.4 expression level × (-0.8123)] + [MIR210HG expression level × 0.1581] + [MAPT-AS1 expression level × (-0.3981)], the prognosis of breast cancer was judged according to the results. When the risk value was > 1.2748, it was the high-risk group, and when the risk value was < 1.2748, it was the low-risk group. The overall survival rate of the high-risk group was significantly lower than that of the low-risk group.

2. A method for constructing a lncRNA breast cancer prognosis model based on claim 1: (1) Data collection: Screen samples containing both mRNA and lncRNA. Randomly divide the samples into a training group and a validation group to establish a prognostic model for lncRNA; (2) Searching for lncRNAs associated with genomic instability: The samples with gene mutation frequency higher than 25% in the screened breast cancer patients were used as the gene unstable group, and the samples with gene mutation frequency lower than 25% were used as the gene stable group. The difference in lncRNA expression between the two groups was compared, and false discovery rate (FDR) < 0.05, log fold change > 1 or < -1 were used as the conditions for screening differential lncRNAs, and differential lncRNAs related to genomic instability were obtained; (3) Construct and verify the lncRNA prognostic model associated with genomic instability: Among the obtained differential lncRNAs, combined with the prognostic information in the above training group, univariate COX analysis and multivariate COX analysis were used to construct the lncRNA gene prognostic model; according to the gene expression level and the COX regression coefficient in the model, the score of each patient in all samples was calculated, and the patients were divided into high-risk group and low-risk group according to the median, so as to evaluate the prognostic value of the model; (4) Relationship between lncRNA prognostic model and mutation: Comparison of gene mutation frequencies between high-risk and low-risk groups differentiated by lncRNA prognostic model; The specific evaluation method is: measuring the expression of lncRNA in tumor samples of breast cancer patients: AL645608.7, U62317.4, MIR210HG, MAPT-AS1, and substituting the above expression into the formula for calculation: [AL645608.7 expression level × 0.0711] + [U62317.4 expression level × (-0.8123)] + [MIR210HG expression level × 0.1581] + [MAPT-AS1 expression level × (-0.3981)], the prognosis of breast cancer was judged according to the results. When the risk value was > 1.2748, it was high risk, and when the risk value was < 1.2748, it was low risk. The overall survival rate of high-risk patients was significantly lower than that of low-risk patients.

Citation Information

Patent Citations

  • Application of model constructed based on RNA binding protein related lncRNA combination in preparation of product for predicting invasive breast cancer prognosis

    CN116287245A

  • Composition for cancer prognosis prediction and kit comprising same

    WO2021241980A1